Xeris Biopharma Holdings, Inc. (NasdaqGS:XERS) is looking for acquisitions. Paul Edick, Chairman and Chief Executive Officer said, "We are focused on potential acquisitions in order to add to our pipeline and most importantly, our commercial business, through acquisition, and those partnerships allow us to generate incremental revenue to do all of the above".
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.905 USD | -1.30% | -4.00% | -18.30% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.30% | 286M | |
+37.47% | 727B | |
-7.88% | 354B | |
+15.60% | 328B | |
-0.44% | 277B | |
+13.47% | 243B | |
+7.35% | 205B | |
-6.42% | 203B | |
+3.86% | 164B | |
-2.00% | 164B |
- Stock Market
- Equities
- XERS Stock
- News Xeris Biopharma Holdings, Inc.
- Xeris Biopharma Holdings Seeks Acquisitions